Immune toxicity remains a diagnosis of exclusion, and multidisciplinary collaboration remains the cornerstone for early diagnosis and treatment.
Chronic Inflammatory Arthritis: An Immune-Related Adverse Event from Cancer Immunotherapy
The emergence of immune-related adverse events (irAEs) from cancer immunotherapy represents a formidable challenge for rheumatologists. Rheumatologist Leonard Calabrese, DO, explains a new classification system for irAEs that may help to focus discussions of these heterogeneous complications.
Polymyalgia Rheumatica-Like Syndrome from Checkpoint Inhibitor Therapy
Is checkpoint inhibitor-related polymyalgia rheumatica (PMR) distinct from the classic rheumatic disease, or does it represent new clinical variants with potentially different pathogenesis, clinical course and treatment responsiveness? Rheumatologist/immunologist Cassandra Calabrese, DO, discusses her research, which identified clinical features that are unusual in idiopathic PMR.
Rheumatic Immune-Related Adverse Events from Checkpoint Inhibitor Therapy: Update
A common occurrence in the age of cancer immunotherapy, immune-related adverse events require multidisciplinary collaboration for investigation and optimal management. Drs. Cassandra and Leonard Calabrese discuss the ever-evolving field and the need for continuing education.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy